Accessing innovative treatments can be a daunting task for patients, especially when dealing with rare or life-threatening conditions. However, Patient Access Programs (PAPs) offer a glimmer of hope, providing eligible patients with early access to investigational drugs or therapies that are not yet approved for general use. In this blog post, we’ll guide you through the process of navigating a Patient Access Program, with a focus on the Early Access Program in India and the role of a managed access program supplier.

Understanding Patient Access Programs:
Patient Access Programs, also known as Early Access Programs or Compassionate Use Programs, are designed to provide patients with serious or life-threatening conditions access to investigational drugs or therapies that have not yet received regulatory approval. These programs are typically available when no other treatment options exist or when the patient has exhausted all other approved treatment options.

The Role of a Managed Access Program Supplier:
A managed access program supplier is a company or organization that specializes in providing access to investigational drugs or therapies through Patient Access Programs. They work closely with pharmaceutical companies, regulatory authorities, and healthcare providers to ensure that eligible patients can access the necessary treatments. As a leading managed access program supplier, Ikris Pharma International plays a crucial role in bridging the gap between pharmaceutical companies and patients in need of investigational drugs or therapies.

Navigating the Early Access Program in India:
In India, the Early Access Program (EAP) is governed by the Central Drugs Standard Control Organization (CDSCO). To access the EAP, patients or their healthcare providers must follow these steps:

Patient Access Programs, such as the Early Access Program in India, offer hope to patients with serious or life-threatening conditions who have exhausted all other treatment options. By working with a managed access program supplier and following the necessary steps, patients can navigate the complex process of accessing investigational drugs or therapies. Remember, each case is unique, and it’s essential to consult with your healthcare provider and the managed access program supplier to ensure that you have the best possible chance of accessing the treatment you need.


Please feel free to contact us:

+91 81302 90915 - +32 4286 1216